Contrast Agents – Pipeline Products by Stage of Development…………………………. 35
Contrast Agents – Pipeline Products by Segment…………………………………………….. 36
Contrast Agents – Pipeline Products by Territory…………………………………………….. 37
Contrast Agents – Pipeline Products by Regulatory Path…………………………………… 38
Contrast Agents – Pipeline Products by Estimated Approval Date……………………… 39
Contrast Agents – Ongoing Clinical Trials………………………………………………………… 40
Contrast Agents Companies – Pipeline Products by Stage of Development………… 41
Contrast Agents – Pipeline Products by Stage of Development…………………………. 49
3B Pharmaceuticals GmbH Pipeline Products & Ongoing Clinical Trials Overview.. 58
3B 202 – Product Status………………………………………………………………………………… 58
3B 202 – Product Description………………………………………………………………………… 58
3B 222 – Product Status………………………………………………………………………………… 59
3B 222 – Product Description………………………………………………………………………… 59
3B 302 – Product Status………………………………………………………………………………… 59
3B 302 – Product Description………………………………………………………………………… 59
3B 402 – Product Status………………………………………………………………………………… 60
3B 402 – Product Description………………………………………………………………………… 60
3B 502 – Product Status………………………………………………………………………………… 60
3B 502 – Product Description………………………………………………………………………… 61
NN – Product Status……………………………………………………………………………………… 61
NN – Product Description……………………………………………………………………………… 61
5M Biomed LLC Pipeline Products & Ongoing Clinical Trials Overview……………….. 62
Molecular Imaging Probe – Product Status……………………………………………………… 62
Molecular Imaging Probe – Product Description……………………………………………… 62
Surface Functionalized Magnetic Iron Oxide Nanorods – Product Status……………. 63
Surface Functionalized Magnetic Iron Oxide Nanorods – Product Description…….. 63
Water Soluble Magnetic Iron Oxide Nanocubes – Product Status………………………. 63
Water Soluble Magnetic Iron Oxide Nanocubes – Product Description………………. 63
Abscint nv Pipeline Products & Ongoing Clinical Trials Overview………………………. 64
ABSCINT-206 – Product Status………………………………………………………………………. 64
ABSCINT-206 – Product Description……………………………………………………………….. 64
AC Immune SA Pipeline Products & Ongoing Clinical Trials Overview………………… 65
TDP-43-PET Tracer – Product Status……………………………………………………………….. 65
TDP-43-PET Tracer – Product Description……………………………………………………….. 65
AccuNovo Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………….. 66
64Cu Labeled NTSR1-Targeting PET Agent – Product Status……………………………… 66
64Cu Labeled NTSR1-Targeting PET Agent – Product Description………………………. 66
AdAlta Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………. 67
Granzyme B PET Imaging Agent – Product Status…………………………………………….. 67
Granzyme B PET Imaging Agent – Product Description…………………………………….. 67
Adamas Nanotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………….. 68
Photo-Hyperpolarizable Nanodiamond-Based 13C Contrast Agent – Product Status………………………………………………………………………………………………………………….. 68
Photo-Hyperpolarizable Nanodiamond-Based 13C Contrast Agent – Product Description…………………………………………………………………………………………………. 68
Adiposs SA Pipeline Products & Ongoing Clinical Trials Overview……………………… 69
ImageBAT – Product Status…………………………………………………………………………… 69
ImageBAT – Product Description……………………………………………………………………. 69
Aestas Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview…………… 70
AP-251 – Product Status……………………………………………………………………………….. 70
AP-251 – Product Description………………………………………………………………………… 70
Affibody AB Pipeline Products & Ongoing Clinical Trials Overview…………………….. 71
GE-226 – Product Status……………………………………………………………………………….. 71
GE-226 – Product Description……………………………………………………………………….. 71
Akrotome Imaging Inc Pipeline Products & Ongoing Clinical Trials Overview……… 72
FIRE Probe – Breast Cancer – Product Status……………………………………………………. 72
FIRE Probe – Breast Cancer – Product Description……………………………………………. 72
Alume Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview……… 73
ALM-488 – Product Status…………………………………………………………………………….. 73
ALM-488 – Product Description……………………………………………………………………… 73
Alume Biosciences Inc – Ongoing Clinical Trials Overview…………………………………. 74
ALM-488 – ALM-488 for Intra-Operative Visualization of Nerves in Head and Neck Surgery………………………………………………………………………………………………………. 75
Alzeca Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview……… 76
ADx Nanoparticle – Product Status………………………………………………………………… 76
ADx Nanoparticle – Product Description…………………………………………………………. 76
Alzeca Biosciences Inc – Ongoing Clinical Trials Overview…………………………………. 77
ADx Nanoparticle – A Phase 1, Controlled, Open-label, Single Dose, Dose-escalation, Clinical Proof-of-concept Study of MRI Enhanced With ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in Patients with Brain Amyloid Deposits as Demonstrated by Amyloid PET……………………………………………………………………………………………….. 78
Amydis Inc Pipeline Products & Ongoing Clinical Trials Overview……………………… 79
AMDX-201 – Product Status………………………………………………………………………….. 79
AMDX-201 – Product Description…………………………………………………………………… 79
AMDX-2011P – Product Status………………………………………………………………………. 80
AMDX-2011P – Product Description……………………………………………………………….. 80
Diagnostic Probe – Creutzfeldt-Jakob Disease – Product Status…………………………. 80
Diagnostic Probe – Creutzfeldt-Jakob Disease – Product Description………………….. 80
Fluorescent Retinal Contrast Agent – Parkinson’s Disease – Product Status………… 81
Fluorescent Retinal Contrast Agent – Parkinson’s Disease – Product Description…. 81
Fluorescent Retinal Tracer – Product Status……………………………………………………. 81
Fluorescent Retinal Tracer – Product Description…………………………………………….. 81
TDP-43 Retinal Tracer – Product Status………………………………………………………….. 82
TDP-43 Retinal Tracer – Product Description…………………………………………………… 82
Amydis Inc – Ongoing Clinical Trials Overview…………………………………………………. 83
AMDX-2011P – A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)…………………………………….. 84
Fluorescent Retinal Contrast Agent – Parkinson’s Disease – Prospective Randomized Open, Blinded Endpoint (PROBE) Study of AMDX-2011P as a Retinal Tracer in Subjects with Neurodegenerative Diseases Associated with Amyloidogenic Proteinopathy…………………………………………………………………………………………….. 85
Antaros Medical AB Pipeline Products & Ongoing Clinical Trials Overview…………. 86
Gadoxetate DCE-MR Imaging Agent – Liver Toxicity – Product Status…………………. 86
Gadoxetate DCE-MR Imaging Agent – Liver Toxicity – Product Description…………. 86
APRINOIA Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview. 87
APN-1701 – Product Status……………………………………………………………………………. 87
APN-1701 – Product Description……………………………………………………………………. 87
aSyn PET Tracer – Product Status…………………………………………………………………… 88
aSyn PET Tracer – Product Description…………………………………………………………… 88
Ascelia Pharma AB Pipeline Products & Ongoing Clinical Trials Overview…………… 89
Orviglance – Product Status………………………………………………………………………….. 89
Orviglance – Product Description…………………………………………………………………… 89
Second Generation Mangoral – Product Status……………………………………………….. 90
Second Generation Mangoral – Product Description……………………………………….. 90
Ascelia Pharma AB – Ongoing Clinical Trials Overview……………………………………… 91
Orviglance – Study Evaluate the Influence of Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Mangoral………………………………….. 92
Astellas Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview…………. 93
ASP5354 – Product Status…………………………………………………………………………….. 93
ASP5354 – Product Description……………………………………………………………………… 93
Augurix SA Pipeline Products & Ongoing Clinical Trials Overview……………………… 94
AUG-BIO 2 – Product Status………………………………………………………………………….. 94
AUG-BIO 2 – Product Description…………………………………………………………………… 94
AUG-BIO 3 – Product Status………………………………………………………………………….. 95
AUG-BIO 3 – Product Description…………………………………………………………………… 95
Auxano Biomedical, LLC. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview……………………………………………………………………………………………………. 96
Diagnostic Agents – Wounds – Product Status…………………………………………………. 96
Diagnostic Agents – Wounds – Product Description………………………………………….. 96
Avelas Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview……… 97
AVB-N-311 – Product Status………………………………………………………………………….. 97
AVB-N-311 – Product Description………………………………………………………………….. 97
AVB-N-312 – Product Status………………………………………………………………………….. 98
AVB-N-312 – Product Description………………………………………………………………….. 98
B-Aegis Life Sciences & Research Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview……………………………………………………………………………………………………. 99
OncoSense – Product Status………………………………………………………………………….. 99
OncoSense – Product Description………………………………………………………………….. 99
Bayer AG Pipeline Products & Ongoing Clinical Trials Overview………………………. 100
Gadoquatrane Contrast Agent – Product Status…………………………………………….. 100
Gadoquatrane Contrast Agent – Product Description…………………………………….. 100
Next Generation Liver MRI Contrast Agent – Product Status…………………………… 101
Next Generation Liver MRI Contrast Agent – Product Description……………………. 101
BBS NanoTechnology Ltd Pipeline Products & Ongoing Clinical Trials Overview.. 102
FCA1 – Gd Containing Paramagnetic MR T1 Contrast Agent – Product Status……. 102
FCA1 – Gd Containing Paramagnetic MR T1 Contrast Agent – Product Description………………………………………………………………………………………………………………… 102
Beckman Research Institute Of The City Of Hope Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………. 103
Calreticulin ImmunoPET Probe – Product Status……………………………………………. 103
Calreticulin ImmunoPET Probe – Product Description…………………………………….. 103
Blaze Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview……….. 104
BLZ-100 – Product Status…………………………………………………………………………….. 104
BLZ-100 – Product Description…………………………………………………………………….. 104
Bracco Imaging SpA Pipeline Products & Ongoing Clinical Trials Overview……….. 105
Iomeron Contrast Agent – Product Status…………………………………………………….. 105
Iomeron Contrast Agent – Product Description……………………………………………… 105
Bracco Imaging SpA – Ongoing Clinical Trials Overview…………………………………… 106
Iomeron Contrast Agent – Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT 107
Brown University Pipeline Products & Ongoing Clinical Trials Overview…………… 108
MR Imaging Probe – Cancer – Product Status…………………………………………………. 108
MR Imaging Probe – Cancer – Product Description…………………………………………. 108
Nanobubble Contrast Agent – Product Status……………………………………………….. 109
Nanobubble Contrast Agent – Product Description………………………………………… 109
Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 110
AI Contrast Agent – Product Status………………………………………………………………. 110
AI Contrast Agent – Product Description……………………………………………………….. 110
Contrast Agent – Prostate Cancer – Product Status………………………………………… 111
Contrast Agent – Prostate Cancer – Product Description…………………………………. 111
PET Imaging Agent – Product Status…………………………………………………………….. 111
PET Imaging Agent – Product Description……………………………………………………… 111
ZD2-Gd3N@C80 – Product Status………………………………………………………………… 112
ZD2-Gd3N@C80 – Product Description…………………………………………………………. 112
Cavatar LLC Pipeline Products & Ongoing Clinical Trials Overview…………………… 113
99mTc Based Contrast Agent – Product Status………………………………………………. 113
99mTc Based Contrast Agent – Product Description………………………………………. 113
Cell2in Pipeline Products & Ongoing Clinical Trials Overview………………………….. 114
Nuclear GSH Tracer – Product Status……………………………………………………………. 114
Nuclear GSH Tracer – Product Description…………………………………………………….. 114
Cellectar Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview… 115
CLR 1502 – Product Status…………………………………………………………………………… 115
CLR 1502 – Product Description…………………………………………………………………… 115
Centre National de la Recherche Scientifique Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………….. 116
Integrin Receptor Targeting Fluorescent Imaging Agent – Tumor Diagnosis – Product Status……………………………………………………………………………………………………….. 116
Integrin Receptor Targeting Fluorescent Imaging Agent – Tumor Diagnosis – Product Description……………………………………………………………………………………………….. 116
Centurion BioPharma Corp Pipeline Products & Ongoing Clinical Trials Overview 117
ACDx – Product Status………………………………………………………………………………… 117
ACDx – Product Description…………………………………………………………………………. 117
Chinese Academy of Sciences Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 118
SNAB Probe – Product Status………………………………………………………………………. 118
SNAB Probe – Product Description……………………………………………………………….. 118
Clarity Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 119
PET Imaging Agent – Amyotrophic Lateral Sclerosis/Brain Perfusion – Product Status………………………………………………………………………………………………………………… 119
PET Imaging Agent – Amyotrophic Lateral Sclerosis/Brain Perfusion – Product Description……………………………………………………………………………………………….. 119
PET Imaging Agent – Fibrosis Panel – Product Status………………………………………. 120
PET Imaging Agent – Fibrosis Panel – Product Description……………………………….. 120
ClearNano Inc Pipeline Products & Ongoing Clinical Trials Overview……………….. 121
ClearGold – Product Status………………………………………………………………………….. 121
ClearGold – Product Description………………………………………………………………….. 121
ClearICG (Indocyanine Green) – Product Status……………………………………………… 121
ClearICG (Indocyanine Green) – Product Description……………………………………… 122
Collagen Medical LLC Pipeline Products & Ongoing Clinical Trials Overview……… 123
[68Ga]CBP8 – Product Status………………………………………………………………………. 123
[68Ga]CBP8 – Product Description……………………………………………………………….. 123
68Ga-CM500 – Product Status…………………………………………………………………….. 123
68Ga-CM500 – Product Description……………………………………………………………… 124
Cosmo Pharmaceuticals NV Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 125
Lumeblue – Product Status………………………………………………………………………….. 125
Lumeblue – Product Description………………………………………………………………….. 125
Curadel LLC Pipeline Products & Ongoing Clinical Trials Overview…………………… 126
cRWD-ZW800-1 – Product Status…………………………………………………………………. 126
cRWD-ZW800-1 – Product Description…………………………………………………………. 126
PanLN Forte-800 – Product Status………………………………………………………………… 127
PanLN Forte-800 – Product Description………………………………………………………… 127
SLN-800 – Product Status……………………………………………………………………………. 127
SLN-800 – Product Description…………………………………………………………………….. 127
ZW800-1 – Product Status…………………………………………………………………………… 128
ZW800-1 – Product Description……………………………………………………………………. 128
ZW800-1 – Prostate Cancer – Product Status…………………………………………………. 128
ZW800-1 – Prostate Cancer – Product Description………………………………………….. 129
CytoSite BioPharma Inc Pipeline Products & Ongoing Clinical Trials Overview….. 130
Diagnostic Imaging Agent – Product Status……………………………………………………. 130
Diagnostic Imaging Agent – Product Description……………………………………………. 130
Daewoong Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 131
Iodixanol Contrast Medium – Product Status………………………………………………… 131
Iodixanol Contrast Medium – Product Description…………………………………………. 131
Ioversol Contrast Medium – Product Status………………………………………………….. 132
Ioversol Contrast Medium – Product Description…………………………………………… 132
Daimroc Imaging Pipeline Products & Ongoing Clinical Trials Overview…………… 133
Silver Nanoparticle Contrast Agent – Product Status………………………………………. 133
Silver Nanoparticle Contrast Agent – Product Description………………………………. 133
Diaprost AB Pipeline Products & Ongoing Clinical Trials Overview…………………… 134
Mab-PET-Ligand – Hu11b6 – Product Status…………………………………………………… 134
Mab-PET-Ligand – Hu11b6 – Product Description…………………………………………… 134
DongKook Lifescience Co Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 135
CT Contrast Agent I – Product Status……………………………………………………………. 135
CT Contrast Agent I – Product Description…………………………………………………….. 135
CT Contrast Agent II – Product Status…………………………………………………………… 136
CT Contrast Agent II – Product Description……………………………………………………. 136
Drexel University Pipeline Products & Ongoing Clinical Trials Overview…………… 137
Ultrasound Contrast Agent – Product Status…………………………………………………. 137
Ultrasound Contrast Agent – Product Description………………………………………….. 137
Duke University Pipeline Products & Ongoing Clinical Trials Overview…………….. 138
18F – Radiolabeled Imaging Agent – Product Status……………………………………….. 138
18F – Radiolabeled Imaging Agent – Product Description………………………………… 138
Edinburgh Molecular Imaging Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 139
EMI-137 – Product Status……………………………………………………………………………. 139
EMI-137 – Product Description…………………………………………………………………….. 140
EMI-200 – Product Status……………………………………………………………………………. 140
EMI-200 – Product Description…………………………………………………………………….. 140
EMI-300/350 – Product Status……………………………………………………………………… 141
EMI-300/350 – Product Description……………………………………………………………… 141
EMI-400 – Product Status……………………………………………………………………………. 141
EMI-400 – Product Description…………………………………………………………………….. 141
EMI-500 – Product Status……………………………………………………………………………. 142
EMI-500 – Product Description…………………………………………………………………….. 142
EMI-600 – Product Status……………………………………………………………………………. 142
EMI-600 – Product Description…………………………………………………………………….. 142
EMP-100 – Product Status…………………………………………………………………………… 143
EMP-100 – Product Description……………………………………………………………………. 143
EMT-100 – Product Status…………………………………………………………………………… 143
EMT-100 – Product Description……………………………………………………………………. 143
EMT-101 – Product Status…………………………………………………………………………… 144
EMT-101 – Product Description……………………………………………………………………. 144
Emory University Pipeline Products & Ongoing Clinical Trials Overview…………… 145
Imaging Agent – Myocarditis – Product Status……………………………………………….. 145
Imaging Agent – Myocarditis – Product Description………………………………………… 145
PET Tracer – Parkinson’s Disease – Product Status………………………………………….. 146
PET Tracer – Parkinson’s Disease – Product Description………………………………….. 146
Enigma Biomedical Group Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 147
CBD2115 – Product Status…………………………………………………………………………… 147
CBD2115 – Product Description…………………………………………………………………… 147
EOS Biosciences Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 148
Eos-002 – Product Status…………………………………………………………………………….. 148
Eos-002 – Product Description…………………………………………………………………….. 148
Eos-004 – Product Status…………………………………………………………………………….. 149
Eos-004 – Product Description…………………………………………………………………….. 149
Expesicor Inc Pipeline Products & Ongoing Clinical Trials Overview…………………. 150
EXP-1801 – Product Status………………………………………………………………………….. 150
EXP-1801 – Product Description…………………………………………………………………… 150
Ferric Contrast Inc Pipeline Products & Ongoing Clinical Trials Overview…………. 151
K720 – Kidney Tumors – Product Status………………………………………………………… 151
K720 – Kidney Tumors – Product Description…………………………………………………. 151
L410 – Liver Tumor – Product Status……………………………………………………………… 151
L410 – Liver Tumor – Product Description……………………………………………………… 152
MP89 – Multipurpose – Product Status…………………………………………………………. 152
MP89 – Multipurpose – Product Description………………………………………………….. 152
GE HealthCare Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 153
Manganese-Based Macrocyclic Magnetic Resonance Imaging (MRI) Contrast Agent – Product Status…………………………………………………………………………………………. 153
Manganese-Based Macrocyclic Magnetic Resonance Imaging (MRI) Contrast Agent – Product Description…………………………………………………………………………………. 153
Non-Lyophilised Sonazoid – Product Status…………………………………………………… 154
Non-Lyophilised Sonazoid – Product Description…………………………………………… 154
GE HealthCare Technologies Inc – Ongoing Clinical Trials Overview…………………. 155
Manganese-Based Macrocyclic Magnetic Resonance Imaging (MRI) Contrast Agent – A Phase I Study to Assess the Safety Profile of Injectable Manganese Contrast Agent……………………………………………………………………………………………………….. 156
Georgia State University Pipeline Products & Ongoing Clinical Trials Overview… 157
Protein Contrast Agent – Product Status………………………………………………………. 157
Protein Contrast Agent – Product Description……………………………………………….. 157
- Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………. 158
Fluorescent Probe – Pancreatic Cancer – Product Status…………………………………. 158
Fluorescent Probe – Pancreatic Cancer – Product Description…………………………. 158
Hana Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview………… 159
HNP-2006 – Product Status…………………………………………………………………………. 159
HNP-2006 – Product Description………………………………………………………………….. 159
Harvard University Pipeline Products & Ongoing Clinical Trials Overview…………. 160
Hyperpolarized MRI Contrast Agent – Product Status…………………………………….. 160
Hyperpolarized MRI Contrast Agent – Product Description……………………………… 160
SPECT Imaging Agent – Neurological Diseases – Product Status……………………….. 161
SPECT Imaging Agent – Neurological Diseases – Product Description……………….. 161
Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 162
CT Molecular Imaging Probe – Product Status……………………………………………….. 162
CT Molecular Imaging Probe – Product Description……………………………………….. 162
Helmholtz Center Dresden Rossendorf Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 163
Functionalized Silicon Nanoparticles – Product Status……………………………………. 163
Functionalized Silicon Nanoparticles – Product Description…………………………….. 163
Helmholtz Center Munich German Research Center for Health and Environment GmbH Pipeline Products & Ongoing Clinical Trials Overview…………………………… 164
Black Nanoparticles – Product Status……………………………………………………………. 164
Black Nanoparticles – Product Description……………………………………………………. 164
Hong Kong Baptist University Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 165
Iridium(III) – Based Probe – Product Status……………………………………………………. 165
Iridium(III) – Based Probe – Product Description…………………………………………….. 165
Hong Kong Polytechnic University Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 166
Imaging-Guided Nanoparticle – Product Status……………………………………………… 166
Imaging-Guided Nanoparticle – Product Description……………………………………… 166
Houston Methodist Research Institute Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 167
pH-Sensitive Dye – Product Status……………………………………………………………….. 167
pH-Sensitive Dye – Product Description………………………………………………………… 167
Hugo W. Moser Research Institute at Kennedy Krieger Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………….. 168
D-Glucose Contrast Agent – Product Status…………………………………………………… 168
D-Glucose Contrast Agent – Product Description…………………………………………… 168
IC Targets AS Pipeline Products & Ongoing Clinical Trials Overview…………………. 169
Mangafodipir – Product Status…………………………………………………………………….. 169
Mangafodipir – Product Description…………………………………………………………….. 169
IC Targets AS – Ongoing Clinical Trials Overview……………………………………………. 170
Mangafodipir – Investigation of Blood-brain-barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-resistant Epilepsy………………………………… 171
ImaginAb Inc Pipeline Products & Ongoing Clinical Trials Overview…………………. 172
Antibody-Based Imaging Agent – Ovarian Cancer – Product Status…………………… 172
Antibody-Based Imaging Agent – Ovarian Cancer – Product Description…………… 172
CD4 Imaging Agent – Product Status…………………………………………………………….. 173
CD4 Imaging Agent – Product Description…………………………………………………….. 173
Macrophage Contrast Agent – Product Status……………………………………………….. 173
Macrophage Contrast Agent – Product Description……………………………………….. 173
Imagion Biosystems Inc Pipeline Products & Ongoing Clinical Trials Overview….. 174
MagSense HER2+ Breast Cancer Imaging Agent – Product Status…………………….. 174
MagSense HER2+ Breast Cancer Imaging Agent – Product Description…………….. 174
Magsense Prostate Cancer Imaging Agent – Product Status……………………………. 175
Magsense Prostate Cancer Imaging Agent – Product Description…………………….. 175
iMax Diagnostic Imaging Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 176
Gadopentetate Dimeglumine – Product Status……………………………………………… 176
Gadopentetate Dimeglumine – Product Description………………………………………. 176
Macrocyclic MRI Contrast Agent – Product Status………………………………………….. 176
Macrocyclic MRI Contrast Agent – Product Description………………………………….. 177
IMRCP Laboratory Pipeline Products & Ongoing Clinical Trials Overview…………. 178
Contrast Agent – Product Status………………………………………………………………….. 178
Contrast Agent – Product Description…………………………………………………………… 178
Indi Molecular Inc Pipeline Products & Ongoing Clinical Trials Overview………….. 179
IO Binding Agent – Product Status……………………………………………………………….. 179
IO Binding Agent – Product Description………………………………………………………… 179
Indian Council of Medical Research Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 180
Imaging Agent – Alzheimer’s Disease – Product Status……………………………………. 180
Imaging Agent – Alzheimer’s Disease – Product Description……………………………. 180
Indian Institute of Technology Delhi Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 181
MRI Imaging Iron Nano-Particles – Product Status…………………………………………. 181
MRI Imaging Iron Nano-Particles – Product Description………………………………….. 181
Inherent Targeting Inc Pipeline Products & Ongoing Clinical Trials Overview……. 182
Near Infrared Nerve-Specific Fluorophore – Product Status……………………………. 182
Near Infrared Nerve-Specific Fluorophore – Product Description…………………….. 182
Inlighta Biosciences LLC Pipeline Products & Ongoing Clinical Trials Overview….. 183
Novel Contrast Agent – Lung Fibrosis – Product Status……………………………………. 183
Novel Contrast Agent – Lung Fibrosis – Product Description……………………………. 183
ProCA32.Collagen – Product Status………………………………………………………………. 184
ProCA32.Collagen – Product Description………………………………………………………. 184
ProCA32.collagen+ – Product Status…………………………………………………………….. 184
ProCA32.collagen+ – Product Description……………………………………………………… 184
ProCA32.CXCR4 – Product Status…………………………………………………………………. 185
ProCA32.CXCR4 – Product Description………………………………………………………….. 185
ProCA32.EGFR – Product Status…………………………………………………………………… 185
ProCA32.EGFR – Product Description……………………………………………………………. 185
ProCA32.GRPR – Product Status…………………………………………………………………… 186
ProCA32.GRPR – Product Description…………………………………………………………… 186
ProCA32.HER2 – Product Status…………………………………………………………………… 186
ProCA32.HER2 – Product Description…………………………………………………………… 187
ProCA32.Integrin – Product Status……………………………………………………………….. 187
ProCA32.Integrin – Product Description……………………………………………………….. 187
ProCA32.PD-L1 – Product Status………………………………………………………………….. 187
ProCA32.PD-L1 – Product Description…………………………………………………………… 188
ProCA32.PSMA – Product Status………………………………………………………………….. 188
ProCA32.PSMA – Product Description…………………………………………………………… 188
ProCA32.vEGFR – Product Status…………………………………………………………………. 189
ProCA32.vEGFR – Product Description………………………………………………………….. 189
InnoMedica Holding AG Pipeline Products & Ongoing Clinical Trials Overview…. 190
Contrast Agent – Tumors – Product Status…………………………………………………….. 190
Contrast Agent – Tumors – Product Description…………………………………………….. 190
Innopharmax Inc Pipeline Products & Ongoing Clinical Trials Overview……………. 191
D0051301 – Product Status…………………………………………………………………………. 191
D0051301 – Product Description………………………………………………………………….. 191
D0131502 – Product Status…………………………………………………………………………. 192
D0131502 – Product Description………………………………………………………………….. 192
Intuitive Surgical Inc Pipeline Products & Ongoing Clinical Trials Overview………. 193
IS-001 Fluorescent Imaging Agent – Product Status……………………………………….. 193
IS-001 Fluorescent Imaging Agent – Product Description………………………………… 193
Inventera Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 194
CT Contrast Agent – Product Status……………………………………………………………… 194
CT Contrast Agent – Product Description………………………………………………………. 194
INV-001 – Product Status…………………………………………………………………………….. 195
INV-001 – Product Description…………………………………………………………………….. 195
INV-002 – Product Status…………………………………………………………………………….. 195
INV-002 – Product Description…………………………………………………………………….. 196
INV-003 – Product Status…………………………………………………………………………….. 196
INV-003 – Product Description…………………………………………………………………….. 196
Nuclear Medicine Contrast Agent – Product Status………………………………………… 197
Nuclear Medicine Contrast Agent – Product Description………………………………… 197
Iowa State University Pipeline Products & Ongoing Clinical Trials Overview…….. 198
Gd5Si4 MRI Contrast Agent – Product Status………………………………………………… 198
Gd5Si4 MRI Contrast Agent – Product Description…………………………………………. 198
Multimodal Contrast Agent – Product Status………………………………………………… 199
Multimodal Contrast Agent – Product Description…………………………………………. 199
Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview.. 200
4th Generation PSA Test – Product Status…………………………………………………….. 200
4th Generation PSA Test – Product Description……………………………………………… 200
PET Imaging Agent – Product Status…………………………………………………………….. 201
PET Imaging Agent – Product Description……………………………………………………… 201
PSMA-Targeted PA Imaging Contrast Agent – Prostate Cancer – Product Status… 201
PSMA-Targeted PA Imaging Contrast Agent – Prostate Cancer – Product Description………………………………………………………………………………………………………………… 202
J-Pharma Co Ltd Pipeline Products & Ongoing Clinical Trials Overview…………….. 203
NKO-028 – PET Diagnostic Probe – Product Status………………………………………….. 203
NKO-028 – PET Diagnostic Probe – Product Description………………………………….. 203
NKO-035 – PET Diagnostic Probe – Product Status………………………………………….. 204
NKO-035 – PET Diagnostic Probe – Product Description………………………………….. 204
King’s College London Pipeline Products & Ongoing Clinical Trials Overview……. 205
Magnetic Resonance Contrast Agent – Product Status……………………………………. 205
Magnetic Resonance Contrast Agent – Product Description……………………………. 205
Knowledgepie Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview…….. 206
Gd-Based Contrast Agent – Product Status……………………………………………………. 206
Gd-Based Contrast Agent – Product Description……………………………………………. 206
Korea University Guro Hospital Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 207
cRGD-ZW800-PEG – Product Status……………………………………………………………… 207
cRGD-ZW800-PEG – Product Description………………………………………………………. 207
ZW700-1C – Product Status…………………………………………………………………………. 208
ZW700-1C – Product Description…………………………………………………………………. 208
LadeRx LLC Pipeline Products & Ongoing Clinical Trials Overview……………………. 209
Chelated Manganese-Based Contrast Agent – Product Status…………………………. 209
Chelated Manganese-Based Contrast Agent – Product Description………………….. 209
Lantheus Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview……. 210
NAV-4694 – Product Status…………………………………………………………………………. 210
NAV-4694 – Product Description………………………………………………………………….. 210
Lantheus Medical Imaging Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 211
LMI 1174 – Product Status…………………………………………………………………………… 211
LMI 1174 – Product Description…………………………………………………………………… 211
RP782 – Product Status………………………………………………………………………………. 212
RP782 – Product Description……………………………………………………………………….. 212
Ligand Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 213
Captisol-Enabled (CE) Iohexol – Product Status……………………………………………… 213
Captisol-Enabled (CE) Iohexol – Product Description………………………………………. 213
Lightpoint Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview……. 214
HARLI – Product Status……………………………………………………………………………….. 214
HARLI – Product Description………………………………………………………………………… 214
Lipella Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 215
LP – 20 – Product Status………………………………………………………………………………. 215
LP – 20 – Product Description………………………………………………………………………. 215
Lipella Pharmaceuticals Inc – Ongoing Clinical Trials Overview………………………… 216
LP – 20 – Human Clinical Study of a Novel Bladder MRI Contrast Agent…………….. 217
Louisiana State University Pipeline Products & Ongoing Clinical Trials Overview. 218
CRC Tumor Imaging Agent – Product Status………………………………………………….. 218
CRC Tumor Imaging Agent – Product Description…………………………………………… 218
Lument AB Pipeline Products & Ongoing Clinical Trials Overview……………………. 219
Lumentin 44 – Product Status……………………………………………………………………… 219
Lumentin 44 – Product Description………………………………………………………………. 219
Macquarie University Pipeline Products & Ongoing Clinical Trials Overview…….. 220
Nanoparticle Imaging Agent – Product Status……………………………………………….. 220
Nanoparticle Imaging Agent – Product Description………………………………………… 220
Mallinckrodt Institute of Radiology Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 221
PET Imaging Tracer – Product Status…………………………………………………………….. 221
PET Imaging Tracer – Product Description…………………………………………………….. 221
Manzanita Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 222
Nervelight – Product Status…………………………………………………………………………. 222
Nervelight – Product Description…………………………………………………………………. 222
Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 223
Mn-PyC3A – Product Status…………………………………………………………………………. 223
Mn-PyC3A – Product Description…………………………………………………………………. 223
MRI Contrast Agent – Product Status……………………………………………………………. 224
MRI Contrast Agent – Product Description……………………………………………………. 224
Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 225
Metal-Free MRI Contrast Agent – Product Status…………………………………………… 225
Metal-Free MRI Contrast Agent – Product Description…………………………………… 225
MRI-Based Calcium Sensor – Product Status…………………………………………………. 226
MRI-Based Calcium Sensor – Product Description………………………………………….. 226
Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview…………………… 227
PET Imaging Agent – Na[18F]PF6 – Product Status………………………………………….. 227
PET Imaging Agent – Na[18F]PF6 – Product Description………………………………….. 227
MediBeacon Inc Pipeline Products & Ongoing Clinical Trials Overview…………….. 228
MB-102 – Product Status…………………………………………………………………………….. 228
MB-102 – Product Description…………………………………………………………………….. 228
MB-112 – Product Status…………………………………………………………………………….. 229
MB-112 – Product Description…………………………………………………………………….. 229
MB-202 – Product Status…………………………………………………………………………….. 229
MB-202 – Product Description…………………………………………………………………….. 229
MB-212 – Product Status…………………………………………………………………………….. 230
MB-212 – Product Description…………………………………………………………………….. 230
MB-301 – Product Status…………………………………………………………………………….. 230
MB-301 – Product Description…………………………………………………………………….. 230
MB-404 – Product Status…………………………………………………………………………….. 231
MB-404 – Product Description…………………………………………………………………….. 231
MediBeacon Inc – Ongoing Clinical Trials Overview……………………………………….. 232
MB-102 – A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium…………………………………………. 233
MB-102 – An Open Label, Multi-Center, Safety and Pharmacokinetic Bridging Study of MB-102 (Relmapirazin) and the Use of the MediBeacon Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function…………………………………………………………………………………………………… 233
Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 234
Zr-89-Transferrin PET Radiotracer – Product Status……………………………………….. 234
Zr-89-Transferrin PET Radiotracer – Product Description………………………………… 234
Microbial Medical Inc Pipeline Products & Ongoing Clinical Trials Overview…….. 235
PET Imaging Agent – Product Status…………………………………………………………….. 235
PET Imaging Agent – Product Description……………………………………………………… 235
Microvascular Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 236
MVT-100 – Product Status…………………………………………………………………………… 236
MVT-100 – Product Description…………………………………………………………………… 236
MVT-101 – Product Status…………………………………………………………………………… 237
MVT-101 – Product Description…………………………………………………………………… 237
MVT-102 – Product Status…………………………………………………………………………… 237
MVT-102 – Product Description…………………………………………………………………… 237
MVT-103 – Product Status…………………………………………………………………………… 238
MVT-103 – Product Description…………………………………………………………………… 238
MVT-104 – Product Status…………………………………………………………………………… 238
MVT-104 – Product Description…………………………………………………………………… 238
MVT-105 – Product Status…………………………………………………………………………… 239
MVT-105 – Product Description…………………………………………………………………… 239
Molecular Theranostics LLC Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 240
Fluorescence Probe – Head And Neck Cancer – Product Status………………………… 240
Fluorescence Probe – Head And Neck Cancer – Product Description………………… 240
MRI Contrast Agent – Prostate Cancer (MT218) – Product Status…………………….. 241
MRI Contrast Agent – Prostate Cancer (MT218) – Product Description……………… 241
MT216 – Product Status……………………………………………………………………………… 241
MT216 – Product Description………………………………………………………………………. 241
MTP219 – Product Status……………………………………………………………………………. 242
MTP219 – Product Description…………………………………………………………………….. 242
Molecular Theranostics LLC – Ongoing Clinical Trials Overview……………………….. 243
MRI Contrast Agent – Prostate Cancer (MT218) – An Open-label Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent (MT218) in Prostate Cancer Patients……………………………………………………………………………………………………. 244
Monash University Pipeline Products & Ongoing Clinical Trials Overview………… 245
Ultrasound Contrast Agent – Product Status…………………………………………………. 245
Ultrasound Contrast Agent – Product Description………………………………………….. 245
Nanosion Co Ltd Pipeline Products & Ongoing Clinical Trials Overview……………. 246
Polymeric Gd Agent – Product Status……………………………………………………………. 246
Polymeric Gd Agent – Product Description……………………………………………………. 246
Nanovista Inc Pipeline Products & Ongoing Clinical Trials Overview………………… 247
Nanotrast – CF800 – Product Status……………………………………………………………… 247
Nanotrast – CF800 – Product Description………………………………………………………. 247
National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 248
Dual-Mode Contrast Agent – Product Status…………………………………………………. 248
Dual-Mode Contrast Agent – Product Description………………………………………….. 248
Neuramedy Co Ltd Pipeline Products & Ongoing Clinical Trials Overview…………. 249
NM-501 – Product Status……………………………………………………………………………. 249
NM-501 – Product Description…………………………………………………………………….. 249
NeuroScientific Biopharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 250
15mS.A. Diagnostic Peptide – Product Status………………………………………………… 250
15mS.A. Diagnostic Peptide – Product Description…………………………………………. 250
Neurovation Labs Inc Pipeline Products & Ongoing Clinical Trials Overview……… 251
NVL1 Diagnostic Tracer – Product Status………………………………………………………. 251
NVL1 Diagnostic Tracer – Product Description……………………………………………….. 251
Nextrast Inc Pipeline Products & Ongoing Clinical Trials Overview………………….. 252
Silicone Bowel DECT Contrast Agent – Product Status……………………………………. 252
Silicone Bowel DECT Contrast Agent – Product Description…………………………….. 252
TaCZ – Product Status…………………………………………………………………………………. 252
TaCZ – Product Description…………………………………………………………………………. 253
Nirvana Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview………. 254
DCE MSOT Contrast Agent – Product Status………………………………………………….. 254
DCE MSOT Contrast Agent – Product Description…………………………………………… 254
Northwestern University Pipeline Products & Ongoing Clinical Trials Overview… 255
Gd(III) Contrast Agent – Product Status………………………………………………………… 255
Gd(III) Contrast Agent – Product Description…………………………………………………. 255
Peptide Amphiphile-Conjugated MRI Contrast Agent – Product Status…………….. 256
Peptide Amphiphile-Conjugated MRI Contrast Agent – Product Description…….. 256
Novara Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview… 257
Contrast Agent – Bone Diseases – Product Status…………………………………………… 257
Contrast Agent – Bone Diseases – Product Description…………………………………… 257
NuvOx Pharma LLC Pipeline Products & Ongoing Clinical Trials Overview………… 258
B7-H3-Targeted Contrast Agent – Breast Cancer – Product Status……………………. 258
B7-H3-Targeted Contrast Agent – Breast Cancer – Product Description…………….. 258
Ultrasound Contrast Agent – Atherosclerotic Plaque – Product Status……………… 259
Ultrasound Contrast Agent – Atherosclerotic Plaque – Product Description………. 259
Ultrasound Contrast Agent – Endocarditis – Product Status…………………………….. 259
Ultrasound Contrast Agent – Endocarditis – Product Description……………………… 259
Ultrasound Contrast Agent – Pancreatic Cancer – Product Status…………………….. 260
Ultrasound Contrast Agent – Pancreatic Cancer – Product Description……………… 260
Ultrasound Contrast Agent – Uveitis – Product Status…………………………………….. 260
Ultrasound Contrast Agent – Uveitis – Product Description……………………………… 260
On Target Laboratories LLC Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 261
Cytalux – Product Status……………………………………………………………………………… 261
Cytalux – Product Description……………………………………………………………………… 261
On Target Laboratories LLC – Ongoing Clinical Trials Overview………………………… 262
Cytalux – A Pilot Study of Near-Infrared Imaging Using the Novel Imaging Agent Cytalux for Adolescent Patients With Metastatic Osteosarcoma Undergoing Pulmonary Metastasectomy……………………………………………………………………….. 263
Cytalux – An Investigator Sponsored Study to Investigate the Safety and Efficacy of CYTALUX (PAFOLACIANINE) INJECTION for the Intraoperative Imaging of Prostate Cancer……………………………………………………………………………………………………… 263
Cytalux – Near-infrared Fluorescence Molecular Imaging of Adalimumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Inflammatory Bowel Disease and Rheumotoid Arthritis……………………………………………………………….. 263
OncoNano Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview…. 264
ONM-100 – Product Status………………………………………………………………………….. 264
ONM-100 – Product Description………………………………………………………………….. 264
ONM-300 – Product Status………………………………………………………………………….. 265
ONM-300 – Product Description………………………………………………………………….. 265
Pegsitacianine Intraoperative Imaging Agent – Product Status………………………… 265
Pegsitacianine Intraoperative Imaging Agent – Product Description………………… 266
OncoNano Medicine Inc – Ongoing Clinical Trials Overview…………………………….. 267
Pegsitacianine Intraoperative Imaging Agent – A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)……………… 268
Ospedaliero Ospedali Galliera Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 269
PET Tracer – 64CuCl2 – Product Status………………………………………………………….. 269
PET Tracer – 64CuCl2 – Product Description…………………………………………………… 269
pHLIP Inc Pipeline Products & Ongoing Clinical Trials Overview………………………. 270
pHLIP ICG – Product Status………………………………………………………………………….. 270
pHLIP ICG – Product Description………………………………………………………………….. 270
pHLIP Inc – Ongoing Clinical Trials Overview………………………………………………….. 271
pHLIP ICG – Phase I/IIa Study of Pre-operative Multiparametric MRI and pHLIP ICG Intra-operative Fluorescence Imaging of Primary Breast Cancer……………………… 272
Photocure ASA Pipeline Products & Ongoing Clinical Trials Overview………………. 273
Hexvix – Product Status………………………………………………………………………………. 273
Hexvix – Product Description……………………………………………………………………….. 273
Photocure ASA – Ongoing Clinical Trials Overview…………………………………………. 274
Hexvix – A Pilot, Real-world Evidence Study of Hexvix in Bladder Cancer Patients of Hainan Province of China……………………………………………………………………………. 275
Hexvix – A Study to Evaluate the Use of Blue Light Cystoscopy Among Non-muscle Invasive Bladder Cancer Subjects and Outcomes in an Equal Access Setting: A Propensity Scored Matched Analysis……………………………………………………………. 275
Hexvix – Blue Light Cystoscopy with Cysview Registry…………………………………….. 275
Hexvix – Flexible Blue Light Cystoscopy with Hexaminolevulinate Provides Opportunity to Finalize Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer in the Outpatient Clinic……………………………………………………………………. 276
Hexvix – Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of Vesical Imaging- Reporting and Data System (VI-RADS) Followed by Primary Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) Versus Conventional White-light TURBT Plus Repeated-TURBT (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) Candidate for Second Look and Resection…. 277
Hexvix – Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection…………………………………………………………………………………… 277
Photolitec LLC Pipeline Products & Ongoing Clinical Trials Overview……………….. 278
PET-ONCO – Product Status…………………………………………………………………………. 278
PET-ONCO – Product Description…………………………………………………………………. 278
Polarean Imaging PLC Pipeline Products & Ongoing Clinical Trials Overview…….. 279
HP 3He – Product Status……………………………………………………………………………… 279
HP 3He – Product Description……………………………………………………………………… 279
XENOVIEW (xenon Xe 129 hyperpolarized) – Pediatrics – Product Status………….. 280
XENOVIEW (xenon Xe 129 hyperpolarized) – Pediatrics – Product Description…… 280
Polyaurum LLC Pipeline Products & Ongoing Clinical Trials Overview………………. 281
Biodegradable Gold Nanoparticles – Product Status………………………………………. 281
Biodegradable Gold Nanoparticles – Product Description……………………………….. 281
Praxis Pharmaceutical SAU Pipeline Products & Ongoing Clinical Trials Overview 282
Microbubble Contrast Agent – Product Status……………………………………………….. 282
Microbubble Contrast Agent – Product Description……………………………………….. 282
Precision Molecular Inc Pipeline Products & Ongoing Clinical Trials Overview….. 283
PMI01 – Product Status………………………………………………………………………………. 283
PMI01 – Product Description……………………………………………………………………….. 283
PMI03 – Product Status………………………………………………………………………………. 284
PMI03 – Product Description……………………………………………………………………….. 284
PMI04 – Product Status………………………………………………………………………………. 284
PMI04 – Product Description……………………………………………………………………….. 284
PMI05 – Product Status………………………………………………………………………………. 285
PMI05 – Product Description……………………………………………………………………….. 285
PMI06 – Product Status………………………………………………………………………………. 285
PMI06 – Product Description……………………………………………………………………….. 285
PMI06-G – Product Status……………………………………………………………………………. 286
PMI06-G – Product Description……………………………………………………………………. 286
PMI07 – Product Status………………………………………………………………………………. 286
PMI07 – Product Description……………………………………………………………………….. 286
Princeton University Pipeline Products & Ongoing Clinical Trials Overview………. 287
Iodine-Based Nanoparticles – Product Status………………………………………………… 287
Iodine-Based Nanoparticles – Product Description…………………………………………. 287
Quest Medical Imaging BV Pipeline Products & Ongoing Clinical Trials Overview 288
Fluorescence Cancer Imaging Molecular Dye – Product Status………………………… 288
Fluorescence Cancer Imaging Molecular Dye – Product Description………………… 288
QurCan Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview… 289
Manganescan (T-MX) – Product Status…………………………………………………………. 289
Manganescan (T-MX) – Product Description………………………………………………….. 289
Radiopharm Theranostics Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 290
RAD201 – Product Status…………………………………………………………………………….. 290
RAD201 – Product Description…………………………………………………………………….. 290
Respiratorius AB Pipeline Products & Ongoing Clinical Trials Overview……………. 291
RESP-3000 – Product Status………………………………………………………………………… 291
RESP-3000 – Product Description…………………………………………………………………. 291
Reveal Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 292
RVP-001 – Product Status……………………………………………………………………………. 292
RVP-001 – Product Description……………………………………………………………………. 292
Rice University Pipeline Products & Ongoing Clinical Trials Overview………………. 293
PET/MRI Contrast Agent – Cancer – Product Status………………………………………… 293
PET/MRI Contrast Agent – Cancer – Product Description………………………………… 293
Roche Diagnostics Pipeline Products & Ongoing Clinical Trials Overview…………. 294
NLRP3 – Product Status………………………………………………………………………………. 294
NLRP3 – Product Description……………………………………………………………………….. 294
Royal College of Surgeons Ireland Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 295
NIR Fluorochrome Imaging Agent – Product Status………………………………………… 295
NIR Fluorochrome Imaging Agent – Product Description………………………………… 295
SANOCHEMIA Pharmazeutika GmbH Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 296
Vidon – Product Status……………………………………………………………………………….. 296
Vidon – Product Description………………………………………………………………………… 296
SBI Pharmaceuticals Co Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 297
Gleolan – Product Status…………………………………………………………………………….. 297
Gleolan – Product Description……………………………………………………………………… 297
SBI Pharmaceuticals Co Ltd – Ongoing Clinical Trials Overview………………………… 298
Gleolan – A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer………………………………. 299
Serac Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………. 300
Maraciclatide – Rheumatoid Arthritis – Product Status…………………………………… 300
Maraciclatide – Rheumatoid Arthritis – Product Description……………………………. 300
Serac Ltd – Ongoing Clinical Trials Overview………………………………………………….. 301
Maraciclatide – Rheumatoid Arthritis – An Observational Study Exploring the Value 99mMaracticaltide Imaging for Predicting Outcomes for Patients With Rheumatoid Arthritis Undergoing Tapering of Therapy…………………………………………………….. 302
SG Endocrine Research LLC Pipeline Products & Ongoing Clinical Trials Overview 303
MRI Imaging Agent – Product Status…………………………………………………………….. 303
MRI Imaging Agent – Product Description…………………………………………………….. 303
Signablok Inc Pipeline Products & Ongoing Clinical Trials Overview…………………. 304
Gadolinium-Based Contrast Agents – Product Status……………………………………… 304
Gadolinium-Based Contrast Agents – Product Description………………………………. 304
Sirtex Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview………….. 305
Imaging Agent – Interventional Oncology – Product Status……………………………… 305
Imaging Agent – Interventional Oncology – Product Description………………………. 305
Society of Nuclear Medicine and Molecular Imaging Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………. 306
68Ga-NOTA-GZP PET/CT – Product Status…………………………………………………….. 306
68Ga-NOTA-GZP PET/CT – Product Description……………………………………………… 306
Solstice Pharmaceuticals BV Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 307
Harmono-T – Product Status……………………………………………………………………….. 307
Harmono-T – Product Description………………………………………………………………… 307
Sonnest Inc Pipeline Products & Ongoing Clinical Trials Overview…………………… 308
Electrast – Product Status……………………………………………………………………………. 308
Electrast – Product Description……………………………………………………………………. 308
Sorbonne Paris Cite Pipeline Products & Ongoing Clinical Trials Overview……….. 309
Optical Imaging Agent – Liver Cancer – Product Status……………………………………. 309
Optical Imaging Agent – Liver Cancer – Product Description……………………………. 309
Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 310
Metabolic MRI Contrast Agent – Product Status……………………………………………. 310
Metabolic MRI Contrast Agent – Product Description…………………………………….. 310
SPION Based Imaging Agents – Product Status………………………………………………. 311
SPION Based Imaging Agents – Product Description……………………………………….. 311
SPAGO Nanomedical AB Pipeline Products & Ongoing Clinical Trials Overview…. 312
SN132D – Product Status…………………………………………………………………………….. 312
SN132D – Product Description…………………………………………………………………….. 312
Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………….. 313
Negative MR Contrast Agents – Product Status……………………………………………… 313
Negative MR Contrast Agents – Product Description……………………………………… 313
Positive MR Contrast Agent – Product Status………………………………………………… 314
Positive MR Contrast Agent – Product Description…………………………………………. 314
Stanford University Pipeline Products & Ongoing Clinical Trials Overview………… 315
B7-H3 Affibody Ligand – Product Status………………………………………………………… 315
B7-H3 Affibody Ligand – Product Description………………………………………………… 315
B7-H3-Targeted Contrast Agent – Breast Cancer – Product Status……………………. 316
B7-H3-Targeted Contrast Agent – Breast Cancer – Product Description…………….. 316
CCS Optical Imaging Agent – Product Status………………………………………………….. 316
CCS Optical Imaging Agent – Product Description………………………………………….. 316
Photoacoustic Imaging – Thyroid Cancer – Product Status………………………………. 317
Photoacoustic Imaging – Thyroid Cancer – Product Description……………………….. 317
PSMA Imaging Agent – Prostate Cancer – Product Status………………………………… 317
PSMA Imaging Agent – Prostate Cancer – Product Description………………………… 317
Stanford University School of Medicine Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 318
Two-Piece Fluorescent Probe – Product Status……………………………………………… 318
Two-Piece Fluorescent Probe – Product Description………………………………………. 318
SunTech Medical Inc Pipeline Products & Ongoing Clinical Trials Overview………. 319
STD-002 – Product Status……………………………………………………………………………. 319
STD-002 – Product Description…………………………………………………………………….. 319
STM-001 – Product Status…………………………………………………………………………… 320
STM-001 – Product Description……………………………………………………………………. 320
SurgiMab SAS Pipeline Products & Ongoing Clinical Trials Overview……………….. 321
SGM-101 – Product Status…………………………………………………………………………… 321
SGM-101 – Product Description…………………………………………………………………… 321
SGM-201 – Product Status…………………………………………………………………………… 322
SGM-201 – Product Description…………………………………………………………………… 322
SGM-301 – Product Status…………………………………………………………………………… 322
SGM-301 – Product Description…………………………………………………………………… 322
SurgiMab SAS – Ongoing Clinical Trials Overview…………………………………………… 323
SGM-101 – A Performance Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for Fluorescence-guided Imaging to Determine Local Extent and Resectability During Surgical Resection of Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment…………………………………. 324
SGM-101 – Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer……………………………………………………. 324
SurgVision GmbH Pipeline Products & Ongoing Clinical Trials Overview…………… 325
BEVA800 – Product Status…………………………………………………………………………… 325
BEVA800 – Product Description…………………………………………………………………… 325
Telix Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview.. 326
TLX007-CDx – Product Status………………………………………………………………………. 326
TLX007-CDx – Product Description……………………………………………………………….. 326
The Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 327
Nanoparticle Contrast Agent – Product Status………………………………………………. 327
Nanoparticle Contrast Agent – Product Description……………………………………….. 327
Theragnostic Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 328
Mangradex – Product Status……………………………………………………………………….. 328
Mangradex – Product Description………………………………………………………………… 328
Theragnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview………….. 329
THG-003 – Product Status……………………………………………………………………………. 329
THG-003 – Product Description……………………………………………………………………. 329
THG-007 – Product Status……………………………………………………………………………. 330
THG-007 – Product Description……………………………………………………………………. 330
Thomas Jefferson University Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 331
Ultrasound Contrast Agent – Product Status…………………………………………………. 331
Ultrasound Contrast Agent – Product Description………………………………………….. 331
TomoWave Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 332
Gold Nanorods Contrast Agent – Product Status……………………………………………. 332
Gold Nanorods Contrast Agent – Product Description……………………………………. 332
Trace Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview……… 333
IT01-08 – Product Status……………………………………………………………………………… 333
IT01-08 – Product Description……………………………………………………………………… 333
University College London Pipeline Products & Ongoing Clinical Trials Overview 334
LipoGlucoCEST – Product Status…………………………………………………………………… 334
LipoGlucoCEST – Product Description…………………………………………………………… 334
University Health Network Pipeline Products & Ongoing Clinical Trials Overview 335
Porphysome Imaging Agent – Product Status………………………………………………… 335
Porphysome Imaging Agent – Product Description………………………………………… 335
University of Arizona Pipeline Products & Ongoing Clinical Trials Overview……… 336
Molecular Scaffold – Contrast Agent – Product Status…………………………………….. 336
Molecular Scaffold – Contrast Agent – Product Description…………………………….. 336
University of Bordeaux Pipeline Products & Ongoing Clinical Trials Overview…… 337
Antibody Based Imaging Agent – Product Status……………………………………………. 337
Antibody Based Imaging Agent – Product Description……………………………………. 337
University of California Davis Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 338
Anti-aVß6 Diabodies – Product Status…………………………………………………………… 338
Anti-aVß6 Diabodies – Product Description…………………………………………………… 338
Nitroxide-Coupled Amyloid Contrast Agents – Product Status…………………………. 339
Nitroxide-Coupled Amyloid Contrast Agents – Product Description…………………. 339
University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 340
Injectable Contrast Agent – Tumor – Product Status……………………………………….. 340
Injectable Contrast Agent – Tumor – Product Description……………………………….. 340
TAM-Sense Agent – Product Status………………………………………………………………. 341
TAM-Sense Agent – Product Description………………………………………………………. 341
University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 342
18F-TRX – Product Status……………………………………………………………………………. 342
18F-TRX – Product Description…………………………………………………………………….. 342
PET Radiotracer – Bacterial Infections – Product Status…………………………………… 343
PET Radiotracer – Bacterial Infections – Product Description…………………………… 343
University of Central Florida Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 344
Activatable NMR/MRI Nanoprobe – Product Status……………………………………….. 344
Activatable NMR/MRI Nanoprobe – Product Description……………………………….. 344
University of Chicago Pipeline Products & Ongoing Clinical Trials Overview……… 345
AuNP-DG Imaging Agent – Product Status…………………………………………………….. 345
AuNP-DG Imaging Agent – Product Description……………………………………………… 345
MRI Imaging Agent – Ovarian Cancer – Product Status……………………………………. 346
MRI Imaging Agent – Ovarian Cancer – Product Description……………………………. 346
University of Edinburgh Pipeline Products & Ongoing Clinical Trials Overview….. 347
Imaging Tool – Lung Infection – Product Status………………………………………………. 347
Imaging Tool – Lung Infection – Product Description………………………………………. 347
University of Gottingen Pipeline Products & Ongoing Clinical Trials Overview….. 348
Iron paraCEST MRI Contrast Agent – Product Status………………………………………. 348
Iron paraCEST MRI Contrast Agent – Product Description……………………………….. 348
University of Illinois at Urbana-Champaign Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………….. 349
OCT Contrast Agent – Product Status……………………………………………………………. 349
OCT Contrast Agent – Product Description……………………………………………………. 349
Plasmon-Resonant Contrast Agent – Product Status………………………………………. 350
Plasmon-Resonant Contrast Agent – Product Description………………………………. 350
University of Louisville Pipeline Products & Ongoing Clinical Trials Overview…… 351
Voltage-Sensitive MRI Myelographic Contrast Agents – Product Status……………. 351
Voltage-Sensitive MRI Myelographic Contrast Agents – Product Description……. 351
University of Michigan Pipeline Products & Ongoing Clinical Trials Overview…… 352
Breast Cancer Diagnosis Pill – Product Status………………………………………………… 352
Breast Cancer Diagnosis Pill – Product Description…………………………………………. 352
University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview…. 353
PET Imaging Probe – Product Status…………………………………………………………….. 353
PET Imaging Probe – Product Description……………………………………………………… 353
University of Missouri Pipeline Products & Ongoing Clinical Trials Overview……. 354
Dual-Biomarker (GRPr/PSMA) Targeting Agent – Prostate Cancer – Product Status………………………………………………………………………………………………………………… 354
Dual-Biomarker (GRPr/PSMA) Targeting Agent – Prostate Cancer – Product Description……………………………………………………………………………………………….. 354
University of North Carolina Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 355
Inhalable Ultrasound Contrast Agent – Product Status…………………………………… 355
Inhalable Ultrasound Contrast Agent – Product Description……………………………. 355
University of Oklahoma Pipeline Products & Ongoing Clinical Trials Overview….. 356
VD-ZW800C – Product Status………………………………………………………………………. 356
VD-ZW800C – Product Description……………………………………………………………….. 356
University of Oxford Pipeline Products & Ongoing Clinical Trials Overview………. 357
Biodegradable MRI Imaging Agent – Product Status………………………………………. 357
Biodegradable MRI Imaging Agent – Product Description……………………………….. 357
Next Generation X-Ray Contrast Agent – Product Status………………………………… 358
Next Generation X-Ray Contrast Agent – Product Description…………………………. 358
Targeted Image Contrast Agent – Product Status…………………………………………… 358
Targeted Image Contrast Agent – Product Description…………………………………… 359
University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 360
Gadolinium Labeled Nanocluster – Product Status…………………………………………. 360
Gadolinium Labeled Nanocluster – Product Description…………………………………. 360
Hyper-CEST MR Contrast Agent – Product Status…………………………………………… 361
Hyper-CEST MR Contrast Agent – Product Description…………………………………… 361
Nanoparticle X-ray Contrast Agent – Product Status………………………………………. 361
Nanoparticle X-ray Contrast Agent – Product Description……………………………….. 361
University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview….. 362
Intraoperative Dual-Labeled Molecular Tracer – Product Status……………………… 362
Intraoperative Dual-Labeled Molecular Tracer – Product Description………………. 362
Microbubble Contrast Agent – Product Status……………………………………………….. 363
Microbubble Contrast Agent – Product Description……………………………………….. 363
University of Tennessee Pipeline Products & Ongoing Clinical Trials Overview…. 364
Fluorocoxib A – Product Status……………………………………………………………………. 364
Fluorocoxib A – Product Description…………………………………………………………….. 364
University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………. 365
[18F]4FN – Product Status…………………………………………………………………………… 365
[18F]4FN – Product Description…………………………………………………………………… 365
University of Texas Southwestern Medical Center Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………. 366
Silica Nanoparticle Ultrasound Contrast Agent – Product Status……………………… 366
Silica Nanoparticle Ultrasound Contrast Agent – Product Description………………. 366
University of Toronto Pipeline Products & Ongoing Clinical Trials Overview…….. 367
MnTCP Imaging Agent – Product Status………………………………………………………… 367
MnTCP Imaging Agent – Product Description………………………………………………… 367
MnTPPS3 Imaging Agent – Product Status…………………………………………………….. 368
MnTPPS3 Imaging Agent – Product Description…………………………………………….. 368
University of Toulouse Pipeline Products & Ongoing Clinical Trials Overview…… 369
Multimodal Imaging Contrast Agent – Product Status…………………………………….. 369
Multimodal Imaging Contrast Agent – Product Description…………………………….. 369
University of Tsukuba Pipeline Products & Ongoing Clinical Trials Overview…….. 370
GPU-327 – Product Status…………………………………………………………………………… 370
GPU-327 – Product Description……………………………………………………………………. 370
University of Virginia Pipeline Products & Ongoing Clinical Trials Overview……… 371
PET Tracer – Pancreatic Cancer – Product Status……………………………………………. 371
PET Tracer – Pancreatic Cancer – Product Description…………………………………….. 371
University of Washington Pipeline Products & Ongoing Clinical Trials Overview.. 372
Thy-1 Microbubble – Product Status…………………………………………………………….. 372
Thy-1 Microbubble – Product Description…………………………………………………….. 372
University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 373
68Ga-FAPI-46 – Product Status…………………………………………………………………….. 373
68Ga-FAPI-46 – Product Description…………………………………………………………….. 373
VA Ann Arbor Healthcare System Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 374
Cholesterol-Analog Contrast Agent – Product Status……………………………………… 374
Cholesterol-Analog Contrast Agent – Product Description………………………………. 374
Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview……… 375
Cox-2 Imaging Agent – Head/Neck And Colon Cancer – Product Status…………….. 375
Cox-2 Imaging Agent – Head/Neck And Colon Cancer – Product Description……… 375
Cyclen Based Imaging Agent – Product Status……………………………………………….. 376
Cyclen Based Imaging Agent – Product Description………………………………………… 376
Hypoxia Sensitive Imaging Agent – Product Status…………………………………………. 376
Hypoxia Sensitive Imaging Agent – Product Description…………………………………. 376
Peptide Targeted Imaging Agent – Product Status…………………………………………. 377
Peptide Targeted Imaging Agent – Product Description………………………………….. 377
Peripheral Benzodiazepine Receptor Ligand Imaging Agent – Product Status……. 377
Peripheral Benzodiazepine Receptor Ligand Imaging Agent – Product Description………………………………………………………………………………………………………………… 377
TPSO Ligand Imaging Agent – Product Status………………………………………………… 378
TPSO Ligand Imaging Agent – Product Description…………………………………………. 378
Vascular BioSciences Pipeline Products & Ongoing Clinical Trials Overview……… 379
Imaging Agent – COVID-19 – Product Status…………………………………………………… 379
Imaging Agent – COVID-19 – Product Description…………………………………………… 379
Imaging Agent – Pulmonary Hypertension – Product Status…………………………….. 380
Imaging Agent – Pulmonary Hypertension – Product Description…………………….. 380
Imaging Agent – Sepsis – Product Status……………………………………………………….. 380
Imaging Agent – Sepsis – Product Description………………………………………………… 380
Vect-Horus SAS Pipeline Products & Ongoing Clinical Trials Overview……………… 381
Imaging Agent – Brain Tumors – Product Status……………………………………………… 381
Imaging Agent – Brain Tumors – Product Description……………………………………… 381
Imaging Agent – Other Tumors – Product Status…………………………………………….. 382
Imaging Agent – Other Tumors – Product Description…………………………………….. 382
Imaging Agent – Pancreatic Cancer – Product Status………………………………………. 382
Imaging Agent – Pancreatic Cancer – Product Description……………………………….. 382
Vergent Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview…… 383
VGT-309 – Product Status……………………………………………………………………………. 383
VGT-309 – Product Description……………………………………………………………………. 383
Vergent Bioscience Inc – Ongoing Clinical Trials Overview………………………………. 384
VGT-309 – A Phase 2, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, in Subjects Undergoing Surgery for Cancer in the Lung……………………………………… 385
VGT-309 – A Phase II, Open-label Study to Evaluate the Safety, Efficacy, Dosing, and Timing of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent for the Intraoperative Identification of Lung Cancer…………………………………………… 385
VGT-309 – Pilot Open Label Study to Determine the Safety and Efficacy of Fluorescent Probe, VGT-309, to Identify Cancerous Colorectal Lesions During White-Light and Fluorescence Augmented Colonoscopy………………………………… 385
Verity Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 386
Diagnostic Agent – Product Status……………………………………………………………….. 386
Diagnostic Agent – Product Description………………………………………………………… 386
Videns og Forskningscenter for Alternativ Behandling Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………. 387
VLS-1 – Product Status………………………………………………………………………………… 387
VLS-1 – Product Description………………………………………………………………………… 387
VLS-2 – Product Status………………………………………………………………………………… 387
VLS-2 – Product Description………………………………………………………………………… 388
VLS-4 – Product Status………………………………………………………………………………… 388
VLS-4 – Product Description………………………………………………………………………… 388
Voyageur Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 389
Iohexol – Product Status……………………………………………………………………………… 389
Iohexol – Product Description……………………………………………………………………… 389
Iopamidol – Product Status…………………………………………………………………………. 390
Iopamidol – Product Description………………………………………………………………….. 390
SmoothX – Product Status…………………………………………………………………………… 390
SmoothX – Product Description…………………………………………………………………… 390
VY-101 – Product Status……………………………………………………………………………… 391
VY-101 – Product Description………………………………………………………………………. 391
VY-102 – Product Status……………………………………………………………………………… 391
VY-102 – Product Description………………………………………………………………………. 391
VY-103 – Product Status……………………………………………………………………………… 392
VY-103 – Product Description………………………………………………………………………. 392
Vyripharm Biopharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 393
VYR-206 – Product Status……………………………………………………………………………. 393
VYR-206 – Product Description…………………………………………………………………….. 393
Washington University in St Louis Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………….. 394
Bioconjugate-Optical Imaging Agent – Product Status……………………………………. 394
Bioconjugate-Optical Imaging Agent – Product Description…………………………….. 394
Colloidal Iron Oxide Contrast Agent – Product Status……………………………………… 395
Colloidal Iron Oxide Contrast Agent – Product Description……………………………… 395
Wayne State University Pipeline Products & Ongoing Clinical Trials Overview….. 396
Next Generation MRI Contrast Imaging Agent – Product Status………………………. 396
Next Generation MRI Contrast Imaging Agent – Product Description……………….. 396
Weizmann Institute of Science Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………………………………………………………… 397
Novel MRI Contrast Agent – Product Status………………………………………………….. 397
Novel MRI Contrast Agent – Product Description…………………………………………… 397
Xemed LLC Pipeline Products & Ongoing Clinical Trials Overview……………………. 398
MagniXene – Product Status……………………………………………………………………….. 398
MagniXene – Product Description………………………………………………………………… 398
Xemed LLC – Ongoing Clinical Trials Overview……………………………………………….. 399
MagniXene – A Prospective Study of Hyperpolarized 129 Xe MRI in in a Pediatric Population with Bronchopulmonary Dysplasia……………………………………………… 400
MagniXene – Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI…………………………….. 400
MagniXene – Hyperpolarized 129 Xenon MRI in a Pediatric Population with Lung Transplant………………………………………………………………………………………………… 400
MagniXene – New Strategies for Pulmonary Assessment in Spinal and Chest Wall Deformity…………………………………………………………………………………………………. 401
MagniXene – Pilot Study of Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation………………………………………….. 401
XN Biotechnologies LLC Pipeline Products & Ongoing Clinical Trials Overview….. 402
RadioCF-PET – Product Status……………………………………………………………………… 402
RadioCF-PET – Product Description………………………………………………………………. 402
Yale University Pipeline Products & Ongoing Clinical Trials Overview………………. 403
PD-L1 BBB PET Imaging Agent – Product Status……………………………………………… 403
PD-L1 BBB PET Imaging Agent – Product Description……………………………………… 403
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd Pipeline Products & Ongoing Clinical Trials Overview………………………………………………………………….. 404
Minims Fluorescein Sodium – Product Status………………………………………………… 404
Minims Fluorescein Sodium – Product Description………………………………………… 404
Glossary……………………………………………………………………………………………………. 482
